Pharma Pulse: MRNA Legal Wars and the Community Pharmacy Shield
BioNTech has filed a Delaware patent‑infringement lawsuit against Moderna, accusing the latter’s next‑generation COVID vaccine mNEXSPIKE of using BioNTech’s streamlined mRNA design. The disputed shot is projected to generate about 55 % of Moderna’s COVID revenue this season, making the case financially significant. Meanwhile, a new pharmacist‑led PRIME program, combining health coaching with a mobile app, doubled the likelihood that prediabetes patients achieved a clinically relevant 5 % weight loss. The findings highlight community pharmacies as pivotal players in metabolic‑health prevention.
Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers
The Supreme Court struck down the broad tariffs imposed under the International Emergency Economic Powers Act, but left Section 232 duties untouched. Because most pharma tariffs were issued under Section 232, the ruling does not eliminate the targeted tariffs on drug imports....
Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...
From Launch to Loss of Exclusivity- Reducing Access and Affordability Barriers Across the Brand Lifecycle
CoverMyMeds outlines how access and affordability challenges evolve across a biopharma brand’s lifecycle, from launch through loss of exclusivity, and offers actionable, data‑driven strategies to mitigate them. The firm emphasizes real‑time analytics, provider‑focused tools, and tailored patient assistance to reduce...
CMS Broadens Drug Price Negotiations to Part B Therapies
The Centers for Medicare & Medicaid Services announced a third round of drug price negotiations that for the first time includes Part B physician‑administered therapies. By extending the Inflation Reduction Act’s pricing provisions to infused medicines, the move pulls doctors into...
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...
Patent Cliff Pressures to Drive Big Pharma M&A
The looming patent cliff, projected to strip up to $300 billion in annual drug sales by 2032, is keeping large pharma firms focused on strategic acquisitions rather than triggering a sudden surge in deal volume. Dan Chancellor of Norstella notes that...
